Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER positive + ESR1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks (New C3) ARV-471 Sensitive : C3 SG-BCC 2023 - 2wk	ARV-471 Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks ARV-471 Sensitive : C3 SG-BCC 2023 - 2 weeks - (New C3)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) DIACC3010 Sensitive : C3 AACR 2023 - 2wk	DIACC3010 Sensitive: C3 – Early Trials AACR 2023 - 2 weeks DIACC3010 Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1